Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
zRvmNqy9c4CvsaL2